Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupTSXV:GSD 39 Days Payable is 0.00 as of Apr. 2026. GuruFocus rates TSXV:GSD with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 703 Biotechnology companies, Devonian Health Group ranks better than 86.49% on this metric.
Devonian Health Group Days Payable Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:GSD vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Devonian Health Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Devonian Health Group's Days Payable for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (TSXV:GSD) has a Days Payable of 0.00 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Devonian Health Group and its competitors. Over the past decade, Devonian Health Group's Days Payable has ranged from 68.98 to 1,088.78. According to the industry distribution chart, Devonian Health Group ranks #95 out of 703 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Devonian Health Group's Days Payable too high?
Devonian Health Group's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 68.98 to a high of 1,088.78. Based on the distribution chart, Devonian Health Group ranks #95 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Devonian Health Group has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #95 out of 703 companies for Days Payable. This places Devonian Health Group in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Devonian Health Group's own Days Payable has ranged from 68.98 to 1,088.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (TSXV:GSD) has a current Days Payable of 0.00. The current Days Payable is 0.00. Devonian Health Group's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Devonian Health Group (TSXV:GSD), the current Days Payable is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
39GF Score
Get the complete analysis for TSXV:GSD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:GSD has been successfully added to your 
